Monoclonal Antibodies Market Trends & Analysis, 2023-2032 

Monoclonal Antibodies Market Size - By Type (Fully Human, Humanized, Chimeric), By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By End-use, Global Forecast (2023-2032)

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast calculation

1.4&nbsp;&nbsp;&nbsp; Covid-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp; Secondary

1.6.1.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.1.2&nbsp;&nbsp;&nbsp;Public sources

1.6.2&nbsp;&nbsp;&nbsp; Primary

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Monoclonal antibodies industry 3600 synopsis

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Type trends

2.1.3&nbsp;&nbsp;&nbsp; Application trends

2.1.4&nbsp;&nbsp;&nbsp; End-use trends

2.1.5&nbsp;&nbsp;&nbsp; Regional trends

Chapter 3&nbsp;&nbsp;&nbsp;Monoclonal Antibodies Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry segmentation

3.2&nbsp;&nbsp;&nbsp; Industry landscape, 2018 &ndash; 2032

3.3&nbsp;&nbsp;&nbsp; Industry impact forces

3.3.1&nbsp;&nbsp;&nbsp; Growth drivers

3.3.1.1&nbsp;&nbsp;&nbsp;Increasing prevalence of chronic and infectious diseases worldwide

3.3.1.2&nbsp;&nbsp;&nbsp;Growing research and development activities

3.3.1.3&nbsp;&nbsp;&nbsp;High rate of adoption and approval in the U.S. and Europe

3.3.1.4&nbsp;&nbsp;&nbsp;Booming biologics market

3.3.1.5&nbsp;&nbsp;&nbsp;Rising applications of monoclonal antibodies

3.3.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.3.2.1&nbsp;&nbsp;&nbsp;High cost of some monoclonal antibody therapeutics

3.3.2.2&nbsp;&nbsp;&nbsp;Stringent regulatory framework

3.4&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4.1&nbsp;&nbsp;&nbsp; By type

3.4.2&nbsp;&nbsp;&nbsp; By application

3.4.3&nbsp;&nbsp;&nbsp; By end-use

3.5&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.7&nbsp;&nbsp;&nbsp; Future trends in monoclonal antibody-based therapeutics

3.8&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.9&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Global company market share analysis, 2022

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix, 2022

4.5&nbsp;&nbsp;&nbsp; Strategic dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Monoclonal Antibodies Market Estimates and Forecast, By Type (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by type

5.2&nbsp;&nbsp;&nbsp; Fully human

5.3&nbsp;&nbsp;&nbsp; Humanized

5.4&nbsp;&nbsp;&nbsp; Chimeric

5.5&nbsp;&nbsp;&nbsp; Other types

Chapter 6&nbsp;&nbsp;&nbsp;Monoclonal Antibodies Market Estimates and Forecast, By Application (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by application

6.2&nbsp;&nbsp;&nbsp; Oncology

6.3&nbsp;&nbsp;&nbsp; Autoimmune diseases

6.4&nbsp;&nbsp;&nbsp; Infectious diseases

6.5&nbsp;&nbsp;&nbsp; Other applications

Chapter 7&nbsp;&nbsp;&nbsp;Monoclonal Antibodies Market Estimates and Forecast, By End-use (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by end-use

7.2&nbsp;&nbsp;&nbsp; Hospitals

7.3&nbsp;&nbsp;&nbsp; Specialty centers

7.4&nbsp;&nbsp;&nbsp; Other end-uses

Chapter 8&nbsp;&nbsp;&nbsp;Monoclonal Antibodies Market Estimates and Forecast, By Region (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by region

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; China

8.4.2&nbsp;&nbsp;&nbsp; Japan

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; Singapore

8.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Argentina

8.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; UAE

8.6.4&nbsp;&nbsp;&nbsp; Egypt

8.6.5&nbsp;&nbsp;&nbsp; Kuwait

8.6.6&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; F. Hoffmann-La Roche Ltd.

9.2&nbsp;&nbsp;&nbsp; AbbVie Inc.

9.3&nbsp;&nbsp;&nbsp; Amgen Inc.

9.4&nbsp;&nbsp;&nbsp; Bristol Myers Squibb

9.5&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson

9.6&nbsp;&nbsp;&nbsp; Merck &amp; Co., Inc.

9.7&nbsp;&nbsp;&nbsp; Regeneron Pharmaceuticals Inc.

9.8&nbsp;&nbsp;&nbsp; Novartis AG

9.9&nbsp;&nbsp;&nbsp; AstraZeneca

9.10&nbsp;&nbsp;&nbsp; Eli Lilly and Company

9.11&nbsp;&nbsp;&nbsp; GlaxoSmithKline plc

9.12&nbsp;&nbsp;&nbsp; Takeda Pharmaceutical Company Limited 
&nbsp;

Monoclonal Antibodies Market

Customize This Report